Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Philadelphia 1 chromosome"'
Autor:
Osman Ilhan, Rıdvan Ali, Zafer Baslar, Ibrahim C. Haznedaroglu, Orhan Ayyildiz, Diyar Z. Akkaynak, Ugur Ozbek, Leylagül Kaynar, Mehmet Sönmez, Demet Aydin, Akif Selim Yavuz, Bülent Ündar, Ilkiz M. Dag, Mustafa Pehlivan, Güray Saydam, Birol Guvenc, Olga Meltem Akay, Simten Dagdas
PubMed ID: 27501474
Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and
Objective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7978eceb03118408c2e8f7f3666597
https://hdl.handle.net/20.500.12605/18279
https://hdl.handle.net/20.500.12605/18279
Autor:
A. Bernal-Vicente, Angel Martinez-Perez, Eva Caparrós-Pérez, Jose Miguel Torregrosa, I. Sánchez-Serrano, Vicente Vicente, Beatriz Sanchez-Vega, Francisca Ferrer-Marín, Gloria Soler, Ana Isabel Antón
Publikováno v:
ANNALS OF HEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Somatic mutations in the CALR gene were recently discovered in a substantial proportion of Philadelphia-negative chronic myeloproliferative neoplasm (cMPN) patients lacking JAK2 and MPL mutations. Somatically acquired defects are not the only pathoge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b508d34f4dd96756138387fbd3e54f
https://pubmed.ncbi.nlm.nih.gov/25482455
https://pubmed.ncbi.nlm.nih.gov/25482455
Autor:
Bizzarri, C., Pinto, R. m., Pitocco, D., Astorri, E., Cappa, M., Hawa, M., Giannone, G., Palermo, A., Maddaloni, E., Leslie, Dr, Pozzilli, P., Altomare, M., Barchetta, Ilaria, Benevento, D., Beretta Anguissola, G., Buzzetti, Raffaella, Capizzi, M., Cappa, M. r., Cavallo, Maria Gisella, Cipolloni, L., Cipponeri, E., Costantino, F., Crino, A., Defeudis, G., Di Stasio, E., Fallucca, S., Fioriti, E., Ghirlanda, G., Guglielmi, C., Khazrai Yeganeh, M., Kyanvash, S., Lauria, A., Maggi, D., Manfrini, S., Maurizi, A. r., Moretti, C., Morviducci, L., Napoli, N., Patera, P., Portuesi, R., Schiaffini, R., Scrocca, R., Spera, S., Strollo, R., Suraci, C., Tubili, C., Tuccinardi, D., Valente, L., Visalli, N.
Publikováno v:
Diabetes Care
Acute lymphoblastic leukemia (ALL) is the most common subtype of leukemia in children. Although ALL and type 1 diabetes appear to be biologically unrelated, there are common threads in both epidemiology and etiology. Rising incidence rates of both AL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7308183dd33cb8ed7a33363d854f967
http://hdl.handle.net/11573/462934
http://hdl.handle.net/11573/462934
Autor:
Fahir Özkalemkaş, Rıdvan Ali, Mutlu Karkucak, Murat Pekgöz, Hulya Ozturk Nazlioglu, Serhat Korkmaz, Tahsin Yakut, Ahmet Tunali, Ferah Budak, Vildan Ozkocaman, Tulay Ozcelik
Imatinib has shown significant clinical and cytogenetic success in the treatment of chronic myeloid leukemia. Although resistance has been observed in a proportion of patients, sudden blastic crisis is a rare event during imatinib therapy. We describ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91eea59e5b394d8c7d6463fb7766132e
http://hdl.handle.net/11452/26745
http://hdl.handle.net/11452/26745
Autor:
Mehmet H. Koseoglu, Hulki Meltem Sönmez, Ekrem Muftuoglu, Gurhan Kadikoylu, Süleyman Demir, Orhan Ayyildiz, Zahit Bolaman
Publikováno v:
Haematologia. 32(1)
Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90932862c6640e3652355e3f72548f7
https://pubmed.ncbi.nlm.nih.gov/12243555
https://pubmed.ncbi.nlm.nih.gov/12243555
Autor:
Michele, Baccarani, Gianantonio, Rosti, Antonio de Vivo, Francesca, Bonifazi, Domenico, Russo, Giovanni, Martinelli, Nicoletta, Testoni, Marilina, Amabile, Mauro, Fiacchini, Enrico, Montefusco, Giuseppe, Saglio, Sante Tura for the Italian Cooperative Study Group on Chronic Myeloid Leukemia, Liberati, Anna Marina, Et, A.
Interferon-alpha (IFN-alpha) has significantly prolonged survival in chronic myeloid leukemia (CML), but some patients do not respond and many responses are not durable. To improve the results, IFN-alpha has been combined with other treatments, but s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9f84061c17eb7de383fa89578a5a23b
http://hdl.handle.net/11391/12065
http://hdl.handle.net/11391/12065
Autor:
Baccarani, M. ac, Tura, S. b, Zuffa, E. b, Russo, D. c, Fanin, R. c, Zaccaria, A. b, Fiacchini, M. b., the italian cooperative study group on chronic myeloid leukemia, Liberati, Anna Marina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3982::d1fe34e2987c41c8d622763304f1adb5
http://hdl.handle.net/11391/1368555
http://hdl.handle.net/11391/1368555